Clinical benefits of bortezomib-containing regimens for newly diagnosed AL amyloidosis with severe cardiac impairment.

MLA

Tsukune, Yutaka, et al. “Clinical Benefits of Bortezomib-Containing Regimens for Newly Diagnosed AL Amyloidosis with Severe Cardiac Impairment.” [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, vol. 57, no. 8, Aug. 2016, pp. 987–93. EBSCOhost, https://doi.org/10.11406/rinketsu.57.987.

APA

Tsukune, Y., Yahata, Y., Sasaki, M., Hiki, M., Tsutsui, M., Hamano, Y., Itoh, S., Miyazaki, T., Dohi, T., Maruyama, M., Gotoh, A., & Komatsu, N. (2016). Clinical benefits of bortezomib-containing regimens for newly diagnosed AL amyloidosis with severe cardiac impairment. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 57(8), 987–993. https://doi.org/10.11406/rinketsu.57.987

Chicago

Tsukune, Yutaka, Yuriko Yahata, Makoto Sasaki, Makoto Hiki, Miyuki Tsutsui, Yasuharu Hamano, Seigo Itoh, et al. 2016. “Clinical Benefits of Bortezomib-Containing Regimens for Newly Diagnosed AL Amyloidosis with Severe Cardiac Impairment.” [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology 57 (8): 987–93. doi:10.11406/rinketsu.57.987.